GSK PLC

Drug pipeline (285)

Asset	Stage	Revenue	Trials	Status
ACTIDIL	approved	—	0	—
ACTIFED	approved	—	3	approved
ACTIFED W/ CODEINE	approved	—	3	approved
ADVAIR DISKUS 100/50	approved	—	63	approved
ADVAIR DISKUS 250/50	approved	—	63	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (3488)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00056407	phase3	completed	2003-03-01	2009-01-01	GlaxoSmithKline	"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
NCT01362348	phase2	terminated	2011-07-07	2012-04-16	GlaxoSmithKline	12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
NCT00373542	phase4	completed	2006-10-01	2007-06-01	GlaxoSmithKline	12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
NCT00495729	phase1	completed	2007-04-18	2007-08-04	GlaxoSmithKline	15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
NCT00318656	phase4	completed	2005-11-01	2007-10-01	GlaxoSmithKline	24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

FDA applications (198)

Application

Approved

Type

Applicant

Products

NDA 215960

2026-06-17

NDA

GLAXOSMITHKLINE LLC

BLA 761458

2025-12-16

BLA

GLAXOSMITHKLINE LLC

BLA 761440

2025-10-23

BLA

GLAXOSMITHKLINE LLC

NDA 218230

2025-03-25

NDA

GLAXOSMITHKLINE LLC

BLA 125819

2025-02-14

BLA

GLAXOSMITHKLINE BIOLOGICALS